Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 17/20 | 0.53 |
| ▸ | ADRB3 | P13945 | 8/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 8/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9069535 | 0.86 | ADRB2 (0.50) | ADRB2ADRB3ADRB1DRD2PGR | |
| SCHEMBL11819468 | 0.85 | ADRB2 (0.49) | ADRB2ADRB3ADRB1DRD2PGR | |
| SCHEMBL3978396 | 0.83 | ADRB2 (0.43) | ADRB2ADRB3ADRB1 | |
| SCHEMBL11816543 | 0.79 | ADRB2 (0.46) | ADRB2ADRB3ADRB1DRD2PGR | |
| SCHEMBL13807382 | 0.77 | ADRB2 (0.53) | ADRB2ADRB3ADRB1DRD2PGR | |
| SCHEMBL11813556 | 0.77 | ADRB2 (0.73) | ADRB2ADRB3ADRB1 | |
| SCHEMBL11817913 | 0.75 | ADRB2 (0.77) | ADRB2ADRB3ADRB1DRD2PGR | |
| SCHEMBL3983366 | 0.75 | ADRB2 (0.41) | ADRB2ADRB3ADRB1DRD2PGR | |
| SCHEMBL3979704 | 0.75 | ADRB2 (0.57) | ADRB2ADRB3ADRB1SLC6A4ADRA1A | |
| SCHEMBL6456434 | 0.74 | ADRB2 (0.51) | ADRB2ADRB3ADRB1DRD2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538127-B2 | Medicinal compounds | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| EP-1554264-B1 | MEDICINAL ARYLETHANOLAMINE COMPOUNDS | GLAXO GROUP LTD (GB) | 2007-08-08 | — | — | EP | disclosed |
| US-20060205790-A1 | Medicinal arylethanolamine compounds | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | US | disclosed |
| US-20060148771-A1 | Medicinal compounds | GLAXO GROUP LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| EP-1592656-A2 | MEDICINAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-11-09 | — | — | EP | disclosed |
| EP-1554264-A2 | MEDICINAL ARYLETHANOLAMINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004071388-A2 | MEDICINAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004037807-A9 | MEDICINAL ARYLETHANOLAMINE COMPOUNDS | GLAXO GROUP LTD (GB) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004037807-A2 | MEDICINAL ARYLETHANOLAMINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148771-A1 | Medicinal compounds | AVPR1B, AVPR2, CYP11B1 | ADRB2 98/4885ADRB3 28/4885ADRB1 16/4885 |
| US-20060205790-A1 | Medicinal arylethanolamine compounds | NAT1, AADAC, AHR | ADRB2 117/4885ADRB3 70/4885ADRB1 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.